$3.14
0.00%
Nasdaq, Aug 30, 01:57 am CET
ISIN
US16385C1045
Symbol
CMMB

Chemomab Therapeutics Ltd - ADR Stock price

$3.14
-1.22 27.98% 1M
-3.58 53.27% 6M
-4.10 56.63% YTD
-4.70 59.95% 1Y
-9.94 75.99% 3Y
-59.49 94.99% 5Y
-688.06 99.55% 10Y
-688.06 99.55% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.27 7.92%
ISIN
US16385C1045
Symbol
CMMB
Industry

Key metrics

Basic
Market capitalization
$17.6m
Enterprise Value
$8.3m
Net debt
positive
Cash
$9.4m
Shares outstanding
103.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
79.8%
Return on Equity
-103.0%
ROCE
-130.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-12.6m | -
EBIT
$-12.7m | $-15.0m
Net Income
$-11.8m | $-4.2m
Free Cash Flow
$-14.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
21.0% | -
EBIT
21.0% | -1.8%
Net Income
21.1% | 69.8%
Free Cash Flow
11.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$-0.1
Short interest
0.1%
Employees
20
Rev per Employee
$0.0
Show more

Is Chemomab Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Chemomab Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

Buy
88%
Hold
13%

Financial data from Chemomab Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.65 3.65
4% 4%
-
- Research and Development Expense 9.03 9.03
28% 28%
-
-13 -13
21% 21%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -13 -13
21% 21%
-
Net Profit -12 -12
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Chemomab Therapeutics Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Chemomab Therapeutics Ltd - ADR Stock News

Neutral
GlobeNewsWire
11 days ago
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C.
Neutral
GlobeNewsWire
18 days ago
— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings— —FDA and Chemomab Align on CMC and Non-Clinical Toxicology Regulatory Path Forward fo...
Neutral
GlobeNewsWire
2 months ago
SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingd...
More Chemomab Therapeutics Ltd - ADR News

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Head office United States
CEO Adi Mor
Employees 20
Founded 2011
Website www.chemomab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today